Study Shows TIL-Based Biomarker Could Predict Checkpoint Inh

An AI-based test developed by South Korean biotech Lunit may improve identification of best responders to immunotherapy when used alongside PD-L1 testing.

Related Keywords

China , Seoul , Soult Ukpyolsi , South Korea , South Korean , Hoon Lee , Tony Mok , Merck Keytruda , Bristol Myers Squibb Opdivo , Genentech Tecentriq , Sungkyunkwan University Samsung Medical Center , Samsung Medical Center , Sungkyunkwan University , Seoul National University Bundang Hospital , Drug Administration , Chinese University Of Hong Kong , Sungkyunkwan University School Of Medicine , Lunit Scope , Clinical Oncology , Chinese University , Hong Kong , Yoon La Choi , Se Hoon Lee , Cancer Genome Atlas , Seoul National University , Seoul National University Bundang , Bristol Myers Squibb , Sungkyunkwan University School , Chan Young Ock ,